Telavancin:
Intravenous glycopeptide
ECMO Dose Adjustment:
YES—in the absence of published data, dose at the higher end of the normal dosing range due to potential for sequestration based on drug characteristics. Monitor for clinical efficacy and toxicity
Renal Impairment Dose Adjustment*:
YES—a decreased dose may be warranted in some patients; consider alternate antimicrobial
CRRT Dose Adjustment:
YES—the dose may need to be increased relative to the renal impairment dose; limited data
Hepatic Impairment Dose Adjustment:
NONE
Adult Dose:
10 mg/kg IV every 24 hours (maximum 750 mg or 1000 mg in obesity)
Pediatric Dose:
No data
Neonatal Dose:
No data